Jubilant Pharmova quarterly results and financials

Jubilant Pharmova (JUBLPHARMA)₹966.00+2.44%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Jubilant Pharmova reported sales of ₹2,234 Cr, up 17.3% from Jun 2025, and net profit of ₹56.07 Cr, down 45.1% year on year. For the year to Mar 2026, sales were ₹8,307 Cr and net profit ₹398 Cr.

Sales (Jun 2026): ₹2,234 Cr
Net profit (Jun 2026): ₹56.07 Cr
Sales (FY Mar 2026): ₹8,307 Cr
Net profit (FY Mar 2026): ₹398 Cr
EPS (Jun 2026): ₹3.56
Borrowings (Mar 2026): ₹3,620 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Jubilant Pharmova quarterly results

₹ crore unless stated; each column is a quarter.

Jubilant Pharmova Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,685	1,681	1,764	1,737	1,757	1,825	1,934	1,904	1,971	2,129	2,297	2,234
Expenses	1,439	1,458	1,488	1,480	1,464	1,536	1,583	1,611	1,626	1,832	1,951	1,980
Operating Profit	241	217	270	251	288	286	344	289	340	288	338	247
OPM %	14.1%	13.1%	15.0%	15.0%	17.1%	16.1%	18.1%	15.0%	17.0%	14.0%	15.0%	11.0%
Other Income	19.08	49.23	−152	411	8.03	−10.04	9.04	12.05	4.02	−19.07	10.04	20.07
Interest	66.18	71.12	73.13	71.11	61.14	56.09	53.10	49.12	50.08	56.12	56.13	54.08
Depreciation	97.22	95.15	101	91.15	91.09	91.19	95.10	98.20	105	121	117	127
Profit before tax	97.65	101	−53.85	498	144	130	205	153	189	92.65	175	85.72
Tax %	36.9%	33.9%	14.9%	4.0%	28.9%	22.9%	27.0%	33.9%	37.0%	39.9%	32.0%	35.0%
Exceptional items	0.00	0.00	−60.93	374	−9.98	−13.96	−0.99	0.00	−3.99	−23.95	−8.98	0.00
Net Profit	62.06	66.06	−62.05	483	102	101	151	102	120	56.05	119	56.07
EPS (Rs)	3.91	4.18	−3.67	30.25	6.44	6.32	9.65	6.45	7.54	3.50	7.51	3.56

Jubilant Pharmova profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Jubilant Pharmova Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	5,760	5,879	7,536	9,130	5,987	6,115	6,145	6,297	6,721	7,254	8,307	8,631
Expenses	4,494	4,510	5,993	7,364	4,428	4,697	4,977	5,500	5,807	6,058	7,019	7,390
Operating Profit	1,251	1,347	1,516	1,738	1,543	1,399	1,146	777	898	1,169	1,256	1,213
OPM %	22.1%	23.1%	20.0%	19.0%	26.0%	23.1%	19.1%	12.0%	13.0%	16.1%	15.0%	14.1%
Other Income	4.01	19.09	36.15	−250	226	264	8.03	−9.04	−76.35	418	7.03	15.06
Interest	372	342	285	221	200	185	145	189	273	240	212	216
Depreciation	347	292	416	372	341	349	383	555	383	369	441	471
Profit before tax	540	736	856	901	1,230	1,129	628	27.90	170	978	612	543
Tax %	28.9%	21.9%	25.9%	35.9%	27.0%	25.9%	33.9%	333.0%	56.9%	15.0%	35.0%	—
Exceptional items	−5.98	−3.99	−2.99	−165	−23.96	−20.95	−1.99	328	31.97	439	−36.94	−36.92
Net Profit	388	575	635	578	898	837	413	−65.11	73.06	837	398	351
EPS (Rs)	24.59	36.15	40.36	36.07	56.34	52.45	25.96	−3.82	4.83	52.70	25.03	22.11
Dividend payout %	12.0%	8.0%	7.0%	12.0%	9.0%	10.0%	19.0%	−130.0%	102.0%	9.0%	20.0%	—

Jubilant Pharmova balance sheet

₹ crore, at each year end.

Jubilant Pharmova Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	15.98	16.00	15.98	16.00	15.98	16.00	16.01	16.00	15.99	16.01	16.01	15.98
Reserves	2,435	2,950	3,416	4,067	4,785	5,584	4,724	5,300	5,377	5,412	6,233	7,059
Borrowings	4,799	4,500	4,053	3,479	4,844	4,816	2,837	3,199	3,684	3,671	2,736	3,620
Other Liabilities	1,377	1,286	1,421	1,911	1,678	1,907	1,198	1,325	1,862	2,251	3,615	4,584
Total Liabilities	8,628	8,753	8,907	9,472	11,324	12,323	8,774	9,841	10,939	11,350	12,600	15,279
Fixed Assets	4,924	5,122	5,122	5,421	5,664	6,360	4,625	4,886	5,202	5,106	5,194	6,984
CWIP	597	611	684	671	901	769	898	1,091	1,562	2,105	3,633	4,040
Investments	39.99	85.01	103	124	115	68.98	241	239	256	42.02	44.02	61.01
Other Assets	3,066	2,934	2,999	3,257	4,643	5,125	3,010	3,625	3,919	4,095	3,730	4,194
Inventories	1,239	1,207	1,224	1,396	1,423	1,851	1,133	1,259	1,385	1,295	1,133	1,237
Trade receivables	818	950	1,004	1,130	1,272	1,293	820	927	961	915	892	1,069
Cash & equivalents	392	344	458	248	1,365	1,395	668	981	1,010	953	1,084	1,263
Total Assets	8,628	8,753	8,907	9,472	11,324	12,323	8,774	9,841	10,939	11,350	12,600	15,279

Jubilant Pharmova cash flow

₹ crore, for each year.

Jubilant Pharmova Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	785	1,102	1,271	1,306	1,125	1,548	1,790	840	663	975	1,076	1,231
Cash from investing activity	−363	−310	−466	−616	−1,022	−268	−730	−324	−475	−598	514	−1,146
Cash from financing activity	−502	−840	−685	−900	656	−1,047	−1,706	−32.91	−157	−431	−1,449	94.75
Net cash flow	−81.95	−51.96	117	−212	760	225	−651	481	29.98	−57.94	132	179
Capex	376	343	466	490	658	576	529	602	816	901	1,119	1,454
Free cash flow	433	759	805	817	472	973	1,268	240	−135	82.83	−37.93	−120
CFO / OP %	141.0%	91.0%	104.0%	103.0%	84.0%	116.0%	155.0%	90.0%	111.0%	131.0%	112.0%	114.0%

Jubilant Pharmova ratios

Working-capital days and returns, by year.

Jubilant Pharmova Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	51	59	62	54	50	78	48	54	55	49	44	46
Inventory days	170	208	224	178	148	464	269	309	269	221	179	171
Days payable	99	106	137	145	106	273	124	139	160	146	158	170
Cash conversion cycle	122	162	149	87	92	268	194	224	165	124	65	47
Working capital days	12	4	50	45	45	62	74	56	57	56	16	13
ROCE %	6.0%	12.9%	14.9%	15.0%	15.9%	15.0%	12.0%	9.9%	3.0%	7.0%	10.0%	8.9%

Jubilant Pharmova: frequently asked questions

What are the latest quarterly results of Jubilant Pharmova?

For the Jun 2026 quarter, Jubilant Pharmova reported sales of ₹2,234 Cr, up 17.3% year on year and net profit of ₹56.07 Cr, down 45.1% year on year. The operating margin was 11.0%.

What is the annual revenue of Jubilant Pharmova?

Jubilant Pharmova's sales for the year to Mar 2026 were ₹8,307 Cr; over the last twelve months they were ₹8,631 Cr.

What is the net profit of Jubilant Pharmova?

Net profit for the year to Mar 2026 was ₹398 Cr, and ₹351 Cr over the last twelve months. Earnings per share over the same trailing period were ₹22.11.

How much debt does Jubilant Pharmova have?

Jubilant Pharmova reported borrowings of ₹3,620 Cr at Mar 2026, against cash and equivalents of ₹1,263 Cr.

What is the free cash flow of Jubilant Pharmova?

Cash from operations was ₹1,231 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹120 Cr.

Loading…